A Swiss biotech firm developing a Covid treatment has seen its share price soar 38,000% this year

Swiss biotech firm Relief Therapeutics has seen its share price climb by nearly 38,000% so far this year, as it develops a drug focused on respiratory failure arising from severe Covid-19.

from Health and Science https://ift.tt/3aa5Fzs
https://ift.tt/eA8V8J
https://ift.tt/2zIUzyH